Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-2 Free Expansion of T Cells with Immunofilaments.

Advanced healthcare materials·2026
Same author

Biomolecule Conjugation Strategy for HAGM Cryogels to Create 3D Immune Niches that Induce Multifunctional T Cells.

ACS biomaterials science & engineering·2025
Same author

Co-delivery of antigen and adjuvant by site-specific conjugation to dendritic cell-targeted Fab fragments potentiates T cell responses.

RSC chemical biology·2025
Same author

Site-directed multivalent conjugation of antibodies to ubiquitinated payloads.

Nature biomedical engineering·2025
Same author

ImmuNet: a segmentation-free machine learning pipeline for immune landscape phenotyping in tumors by multiplex imaging.

Biology methods & protocols·2025
Same author

Reprogramming the melanoma and immunosuppressive myeloid cells with esomeprazole-loaded PLGA nanoparticles.

iScience·2025

Related Experiment Video

Updated: May 22, 2026

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Targeting nanoparticles to dendritic cells for immunotherapy.

Luis J Cruz1, Paul J Tacken, Felix Rueda

  • 1Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.

Methods in Enzymology
|May 10, 2012
PubMed
Summary

Targeted nanodelivery systems enhance immune responses by delivering vaccine components to dendritic cells (DCs). Optimizing particle size and targeting DC receptors are crucial for effective in vivo vaccination strategies.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: May 22, 2026

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

  • Immunology
  • Nanotechnology
  • Vaccine Development

Background:

  • Dendritic cells (DCs) are crucial for initiating adaptive immunity and are utilized in cancer and infectious disease immunotherapy.
  • Targeted nanodelivery of vaccine components (antigens, adjuvants) to DCs in vivo is a promising strategy to boost immune responses.
  • Challenges include specific DC delivery and avoiding uptake by other cells, with particle size and receptor targeting being key factors.

Purpose of the Study:

  • To discuss the rationale behind particle-based vaccines.
  • To provide an overview of current antigen-delivery vehicles for DC targeting.
  • To explore the development of safe and effective vaccine delivery systems.

Main Methods:

  • Review of literature on nanodelivery systems for vaccines.
  • Discussion of particle characteristics (size) for lymph node penetration and DC access.
  • Exploration of active targeting strategies using DC-specific receptors.
  • Focus on specific delivery vehicles: liposomes, PLGA polymers, and gold nanoparticles.

Main Results:

  • Particle size is critical for lymph node penetration and reaching resident DCs.
  • Active targeting of DC-specific receptors enhances vaccine delivery specificity.
  • Liposomes, PLGA polymers, and gold nanoparticles are promising platforms for vaccine development.

Conclusions:

  • Nanodelivery systems offer a promising approach to enhance vaccine efficacy.
  • Careful consideration of particle size and targeting ligands is essential for successful DC-targeted vaccination.
  • Further development of these systems aims for safe and effective vaccines against cancer and infectious diseases.